CYPHERPUNK TECHNOLOGIES INC.
CYPH evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $383.3M
- Lead Asset:
- sirexatamab (Phase 2)
What it means
What to watch
Prepared research question
What matters most for CYPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CYPH
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is a public biotechnology company developing two drug candidates — sirexatamab (Phase 2, colorectal cancer) and FL-501 (preclinical, cachexia) — while also operating a privacy technology/digital asset treasury strategy; it has no approved therapeutic products and relies on external financing to fund operations.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for CYPHERPUNK TECHNOLOGIES INC..
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is a public biotechnology company developing two drug candidates — sirexatamab (Phase 2, colorectal cancer) and FL-501 (preclinical, cachexia) — while also operating a privacy technology/digital asset treasury strategy; it has no approved therapeutic products and relies on external financing to fund operations.
- Cash & equivalents of $7.6M as of 2026-06-30 [sec].
- Net income of $39.4M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $139.3M as of 2026-06-30 [sec].
- Lead candidate sirexatamab (DKN-01) is in Phase 2 for colorectal cancer with FDA Fast Track status [pipeline].
- Preclinical candidate FL-501 targets cachexia via GDF-15 inhibition, developed under a collaboration with Adimab [pipeline].
What works
- Sirexatamab has received FDA Fast Track designation, which may expedite development and review [pipeline].
- The company has a collaboration with Tempus to leverage real-world evidence on DKK1 levels in various cancers [pipeline].
- FL-501 is being developed under a collaboration agreement with Adimab, potentially reducing early-stage costs and risk [pipeline].
What to weigh
- The company does not expect to generate revenue from therapeutic drug sales unless and until it completes development and obtains marketing approval, which is subject to significant uncertainty and will take a number of years [sec_mda · as of 2026-03-16].
- Additional capital will be needed prior to commercialization of sirexatamab or any other product candidate; if funding is not obtained, the company could be forced to eliminate programs and reduce operating expenses [sec_mda · as of 2026-08-12].
- There is no assurance that profitable operations from either the privacy technology/digital asset treasury strategy or biotechnology operations can be sustained on a continuing basis [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
No revenue from therapeutic drug sales until marketing approval
“We do not expect to generate revenue from therapeutic drug product sales unless and until we successfully complete development and obtain marketing approval for one or more of our product candidates, which we expect will take a number of years and is subject to significant uncertainty.”
SEC MD&A · March 16, 2026
Need for additional capital prior to commercialization
“we will need to raise additional capital prior to the commercialization of sirexatamab or any other product candidate.”
SEC MD&A · March 16, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has no FDA-approved therapeutic products; all candidates are in development with uncertain timelines [sec_mda · as of 2026-03-16].
- Funding dependency — Future operations depend on raising additional capital; failure could force program cuts and delay expansion [sec_mda · as of 2026-08-12].
- Uncertain profitability — No assurance that profitable operations from either business line can be sustained [sec_mda · as of 2026-08-12].
What to watch
- Progress of sirexatamab Phase 2 trial in colorectal cancer and any updates on regulatory interactions [pipeline].
- Advancement of FL-501 from preclinical to clinical development [pipeline].
- Company's ability to secure additional funding or partnerships to extend cash runway beyond the $7.6M reported as of 2026-06-30 [sec].
- Any changes in the privacy technology/digital asset treasury strategy that could affect overall financial condition [sec_mda · as of 2026-08-12].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run CYPHERPUNK TECHNOLOGIES INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CYPHERPUNK TECHNOLOGIES INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.03 · 18% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
41
Total value held
$5.8M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 2,342,174 | $1.9M |
| vanguard capital management llc | 1,818,414 | $1.4M |
| renaissance technologies llc | 725,120 | $576K |
| geode capital management, llc | 571,068 | $454K |
| vanguard fiduciary trust co | 297,086 | $236K |
| susquehanna international group, llp | 262,953 | $209K |
| ubs group ag | 171,068 | $136K |
| lpl financial llc | 162,494 | $129K |
| state street corp | 140,113 | $111K |
| group one trading llc | 107,416 | $85K |
Showing top 10 of 41 institutional holders of CYPHERPUNK TECHNOLOGIES INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 11.7%
- Days to cover
- 3.8
- Shares short
- 8,920,114
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CYPH short interestGovernance
Frequently asked questions
What is the AI investment thesis for CYPHERPUNK TECHNOLOGIES INC.?
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is a public biotechnology company developing two drug candidates — sirexatamab (Phase 2, colorectal cancer) and FL-501 (preclinical, cachexia) — while also operating a privacy technology/digital asset treasury strategy; it has no approved therapeutic products and relies on external financing to fund operations.
What is CYPHERPUNK TECHNOLOGIES INC.'s lead drug candidate?
CYPHERPUNK TECHNOLOGIES INC.'s most advanced tracked candidate is sirexatamab (Phase 2) for colorectal cancer.
Who is the CEO of CYPHERPUNK TECHNOLOGIES INC.?
Mr. Douglas E. Onsi J.D. is the chief executive officer of CYPHERPUNK TECHNOLOGIES INC. (CYPH).
Where is CYPHERPUNK TECHNOLOGIES INC. headquartered?
CYPHERPUNK TECHNOLOGIES INC. (CYPH) is headquartered in Cambridge, MA, United States.
What therapeutic areas does CYPHERPUNK TECHNOLOGIES INC. focus on?
CYPHERPUNK TECHNOLOGIES INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.